Licopid [GMDP]


Licopid® (or Lycopid) is the immunomodulator containing a complete synthetic analog of natural GMDP or glucosaminyl muramyl dipeptide.

Once in the body, Lycopid® mimics the natural process of detecting fragments of peptidoglycan bacteria. Thus, the effect of the drug is as close as possible to the process of natural immunoregulation.

GMDP also demonstrates other useful properties obtained in experimental studies: antitumor and antimetastatic effects and adjuvant properties (increased antibody production during immunization, which is especially important when introducing killed or "weakened" antigens). These are the new promising areas of scientific research for the future.

Can assist in treating:

  • Chronic infections of the upper and lower respiratory tract;
  • Acute and chronic purulent-inflammatory diseases of skin and soft tissues (pyoderma, furunculosis, etc.), including purulent-septic postoperative complications
  • Herpetic infection;
  • Sexually transmitted infections (papilloma viral infection, chronic trichomoniasis);
  • Psoriasis (including psoriatic arthritis);
  • Pulmonary tuberculosis;
  • Prevention and reduction of the seasonal incidence of acute respiratory infections and the frequency of exacerbations of chronic diseases of ENT organs and upper and lower respiratory tract. 

Dosage and Administration

Lycopid® is administered orally or sublingually in the fasting state, 30 minutes before meals.


  • Hypersensitivity to the drug components;
  • Pregnancy and lactation;
  • Autoimmune thyroiditis in the acute phase;
  • Conditions accompanied by febrile temperature (> 38°C or > 100.4°F);
  • Rare congenital metabolic disorders;
  • Child age for Licopid® 10 mg.